Indobufen plus clopidogrel DAPT reduced bleeding risk while preserving ischemic protection during 12 months post-PCI in patients with multivessel coronary disease.
Does indobufen-based DAPT reduce bleeding events and preserve ischemic protection in patients with multivessel coronary disease undergoing drug-eluting stent implantation?
Indobufen plus clopidogrel reduces bleeding risk while preserving ischemic protection compared to aspirin plus clopidogrel in patients with multivessel coronary disease up to 1 year post-PCI.
Absolute Event Rate: 0% vs 0%
Abstract Background It remains unclear whether indobufen-based dual antiplatelet therapy (DAPT) preserves ischemic protection while limiting bleeding risk in patients with multivessel coronary disease (MVD). This study aimed to investigate the efficacy and safety of indobufen-based DAPT in patients with MVD. Methods Patients in the OPTION trial were stratified based on the presence of MVD. We compared the ischemic and bleeding risks of indobufen-based DAPT (indobufen 100mg twice a day plus clopidogrel 75mg/d for 12 months) versus conventional DAPT (aspirin 100mg/d plus clopidogrel 75mg/d for 12 months) in patients with and without MVD, using landmarks at 6 months and 1 year post-percutaneous coronary intervention (PCI). Results Patients with MVD tended to be older and contained a higher prevalence of high-risk features. Compared with patients without MVD, those with MVD were at higher risk for net adverse clinical events and ischemic events. The risk of ischemic events between indobufen-based DAPT versus conventional DAPT was similar either in patients with MVD or without MVD during the first and second 6 months. During the first 6 months, indobufen-based DAPT decreased the risk of bleeding events consistently in patients with and without MVD. Of note, during the second 6 months, indobufen-based DAPT continually decreased the risk of bleeding events in patients with MVD but not in those without MVD. Conclusions In patients with MVD, indobufen plus clopidogrel DAPT compared to aspirin plus clopidogrel DAPT could reduce the risk of bleeding events while preserving ischemic protection during both the first and second 6 months post-PCI. Indobufen presents an effective option for patients with MVD, especially those at high ischemic risk requiring DAPT beyond 6 months post-PCI.Efficacy of indobufen in MVD Safety of indobufen in MVD
Xu et al. (Sat,) reported a other. Indobufen plus clopidogrel DAPT reduced bleeding risk while preserving ischemic protection during 12 months post-PCI in patients with multivessel coronary disease.